---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-026439"
form_type: "8-K"
ticker: "VYNE"
cik: "0001566044"
company_name: "VYNE Therapeutics Inc."
filed_at: "2026-03-11T23:59:59+00:00"
generated_at: "2026-05-15T14:47:17.569805+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# VYNE receives Nasdaq extension to Sept 7, 2026 to regain $1 bid price compliance

## Summary
- Company failed to regain minimum $1.00 bid price by original March 10, 2026 deadline.
- Nasdaq granted additional 180 calendar days, until September 7, 2026, to cure deficiency.
- VYNE may consider a reverse stock split to meet the bid price requirement.
- Common stock continues trading on Nasdaq Capital Market under symbol VYNE during extension.

## SEC filing metadata
- accession: 0001104659-26-026439
- form_type: 8-K
- ticker: VYNE
- cik: 0001566044
- company_name: VYNE Therapeutics Inc.
- filed_at: 2026-03-11T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1566044/000110465926026439/0001104659-26-026439-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1566044/000110465926026439/tm268461d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-026439
- JSON: https://secwatch.observer/filing/0001104659-26-026439.json
- Plain text: https://secwatch.observer/filing/0001104659-26-026439.txt

## Source-grounded claims
- claim_id: 793c983085e2fd16e30bb4563a31c34945ee08ac
  claim: VYNE Therapeutics Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).
  evidence_excerpt: March 11, 2026, the Company received a letter (the “Extension Notice”) from Nasdaq notifying the Company that its request for an extension to regain compliance with the minimum bid price requirement has been granted, and the Company has an additional 180 calendar days, or until September 7, 2026, to regain compliance with the minimum bid price requirement. Nasdaq’s determination was based on the Company meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on the Nasdaq Capital Market with the exception of t
  evidence_url: https://www.sec.gov/Archives/edgar/data/1566044/000110465926026439/0001104659-26-026439-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.